01—Abstract
Summary
Summary of the 10-K filed September 30, 1996. Cited figures are marked; the original filing is the authoritative source.
Archer-Daniels-Midland's fiscal 1996 10-K (year ended June 30, 1996) reports record net sales and other operating income of $13.3 billiona, up 5% from $12.7 billion, driven mainly by a 7% increase in average selling prices.
However, profitability weakened sharply: net earnings fell 13% to $695.9 millionb ($1.27 per share) from $795.9 million ($1.40 per share in the prior year, as reported in the filing's statements), as gross profit declined $278 million to $1.36 billion. Management attributed the margin squeeze to a 16% rise in raw material commodity costs that outpaced selling price gains, along with divestitures of Supreme Sugar and British Arkady and the contribution of formula feed operations to a joint venture. Selling, general and administrative expenses rose to $450 million, largely due to legal costs.
Other income improved to $140 millionc from a loss of $32 million, helped by $109 million in securities gains. Balance sheet strength remains a clear positive. Working capital was $2.75 billion, cash and marketable securities totaled about $1.4 billion in current holdings, shareholders' equity reached $6.1 billion, and the long-term debt-to-capital ratio was about 23%.
Credit ratings were AA- (S&P) and Aa2 (Moody's). The company returned capital through $260 milliond of share repurchases and dividends that rose to $0.17 per share from $0.08. The dominant risk for investors is legal and regulatory exposure stemming from a federal grand jury investigation into price fixing in lysine, citric acid, and high fructose corn syrup.
Two executive officers, Michael D. Andreas and Terrance S.
Wilson, have been told they are targets, and the company has agreed to pay $30 million and $35 million to settle securities and citric acid class actions, with a $25 million lysine settlement already paid. Management believes the ultimate resolution will not be materially adverse to consolidated financial condition, though quarterly results could be affected if outcomes are unfavorable.
02—Key points
Key Highlights
- Record net sales and other operating income of $13.3 billion, up 5% year over year, driven by a 7% rise in average selling prices
- Net earnings declined 13% to $695.9 million ($1.27 per share) as higher raw material costs (up 16%) compressed gross profit by $278 million to $1.36 billion
- Oilseed products remained the largest segment at 61% of sales ($8.1 billion), while corn products contributed $2.6 billion and wheat and other milled products $1.6 billion
- Strong liquidity: $2.75 billion working capital, roughly $1.4 billion in cash and marketable securities, and $370 million in unused bank credit lines
- Shareholders' equity rose to $6.1 billion, with long-term debt at about 23% of total capital and AA-/Aa2 credit ratings maintained
- Antitrust exposure is significant: grand jury investigations in lysine, citric acid, and high fructose corn syrup, with two executives identified as targets and $90 million in class action settlements announced or paid
- Capital returned to shareholders through $260 million in treasury stock purchases and dividends increasing to $0.17 per share from $0.08
03—Questions
Frequently Asked Questions
Why did earnings decline despite record sales?
Sales rose on higher average selling prices, but raw material commodity costs rose about 16%, which absorbed the pricing gains. Gross profit fell $278 million, and SG&A increased $21 million, mainly from legal expenses. Partly offsetting this, other income swung to a $140 million gain from a $32 million loss, largely due to $109 million in securities gains. The result was net earnings of $695.9 million, down from $795.9 million.
How significant is the antitrust litigation to the company's outlook?
It is the main legal risk. A federal grand jury is investigating price fixing in lysine, citric acid, and high fructose corn syrup, and two executives are considered targets. Settlements include $25 million paid for the federal lysine class action and agreements to pay $30 million (securities) and $35 million (citric acid). Management says the ultimate outcome should not materially affect consolidated financial condition, but quarterly results could be hit if an unfavorable resolution occurs, and some matters cannot yet be estimated and have no reserves.
Is the balance sheet strong enough to support growth and shareholder returns?
Yes. The company had $2.75 billion in working capital, a 2.7 current ratio, about $1.4 billion in cash and marketable securities, and $6.1 billion in equity. Long-term debt is roughly 23% of total capital, and it holds $370 million in unused credit lines. Capital expenditures were $754 million, and the company continued buybacks and a higher dividend.
What drove the company's business mix and growth in fiscal 1996?
Oilseed processing was the core, representing 61% of net sales and rising 6% to $8.1 billion on strong protein meal demand. Corn products grew 3% to $2.6 billion through fuel alcohol and bioproducts such as citric acid, lysine, and MSG. Wheat and other milled products rose 19% on higher prices, while divestitures of Supreme Sugar and British Arkady reduced the 'other products' category by about 16%.
04—Continue